227 related articles for article (PubMed ID: 23512668)
1. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults.
Ince I; de Wildt SN; Wang C; Peeters MY; Burggraaf J; Jacqz-Aigrain E; van den Anker JN; Tibboel D; Danhof M; Knibbe CA
Clin Pharmacokinet; 2013 Jul; 52(7):555-65. PubMed ID: 23512668
[TBL] [Abstract][Full Text] [Related]
2. Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.
Brussee JM; Vet NJ; Krekels EHJ; Valkenburg AJ; Jacqz-Aigrain E; van Gerven JMA; Swart EL; van den Anker JN; Tibboel D; de Hoog M; de Wildt SN; Knibbe CAJ
Br J Clin Pharmacol; 2018 Feb; 84(2):358-368. PubMed ID: 29072785
[TBL] [Abstract][Full Text] [Related]
3. The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study.
van Groen BD; Krekels EHJ; Mooij MG; van Duijn E; Vaes WHJ; Windhorst AD; van Rosmalen J; Hartman SJF; Hendrikse NH; Koch BCP; Allegaert K; Tibboel D; Knibbe CAJ; de Wildt SN
Clin Pharmacol Ther; 2021 Jan; 109(1):140-149. PubMed ID: 32403162
[TBL] [Abstract][Full Text] [Related]
4. First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.
Brussee JM; Yu H; Krekels EHJ; de Roos B; Brill MJE; van den Anker JN; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):374-383. PubMed ID: 29745466
[TBL] [Abstract][Full Text] [Related]
5. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.
Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428
[TBL] [Abstract][Full Text] [Related]
6. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
Abduljalil K; Pan X; Pansari A; Jamei M; Johnson TN
Clin Pharmacokinet; 2020 Apr; 59(4):501-518. PubMed ID: 31587145
[TBL] [Abstract][Full Text] [Related]
7. Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults.
van Rongen A; Brill MJE; Vaughns JD; Välitalo PAJ; van Dongen EPA; van Ramshorst B; Barrett JS; van den Anker JN; Knibbe CAJ
Clin Pharmacokinet; 2018 May; 57(5):601-611. PubMed ID: 28785981
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.
Brussee JM; Yu H; Krekels EHJ; Palić S; Brill MJE; Barrett JS; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
Pharm Res; 2018 Jul; 35(9):182. PubMed ID: 30062590
[TBL] [Abstract][Full Text] [Related]
9. Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years.
Ince I; de Wildt SN; Peeters MY; Murry DJ; Tibboel D; Danhof M; Knibbe CA
Ther Drug Monit; 2012 Aug; 34(4):381-9. PubMed ID: 22660604
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
[TBL] [Abstract][Full Text] [Related]
11. Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model.
Völler S; Flint RB; Beggah F; Reiss I; Andriessen P; Zimmermann LJI; van den Anker JN; Liem KD; Koch BCP; de Wildt S; Knibbe CAJ; Simons SHP
J Clin Pharmacol; 2019 Oct; 59(10):1300-1308. PubMed ID: 31093992
[TBL] [Abstract][Full Text] [Related]
12. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
Björkman S
Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics.
Lee TC; Charles BG; Harte GJ; Gray PH; Steer PA; Flenady VJ
Anesthesiology; 1999 Feb; 90(2):451-7. PubMed ID: 9952152
[TBL] [Abstract][Full Text] [Related]
14. A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children.
Brussee JM; Krekels EHJ; Calvier EAM; Palić S; Rostami-Hodjegan A; Danhof M; Barrett JS; de Wildt SN; Knibbe CAJ
AAPS J; 2019 Jun; 21(5):81. PubMed ID: 31250333
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children.
Vet NJ; Brussee JM; de Hoog M; Mooij MG; Verlaat CW; Jerchel IS; van Schaik RH; Koch BC; Tibboel D; Knibbe CA; de Wildt SN;
Am J Respir Crit Care Med; 2016 Jul; 194(1):58-66. PubMed ID: 26796541
[TBL] [Abstract][Full Text] [Related]
16. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
[TBL] [Abstract][Full Text] [Related]
17. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model.
Peeters MY; Allegaert K; Blussé van Oud-Alblas HJ; Cella M; Tibboel D; Danhof M; Knibbe CA
Clin Pharmacokinet; 2010 Apr; 49(4):269-75. PubMed ID: 20214410
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates.
Ahsman MJ; Hanekamp M; Wildschut ED; Tibboel D; Mathot RA
Clin Pharmacokinet; 2010 Jun; 49(6):407-19. PubMed ID: 20481651
[TBL] [Abstract][Full Text] [Related]
19. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Wildt SN; de Hoog M; Vinks AA; van der Giesen E; van den Anker JN
Crit Care Med; 2003 Jul; 31(7):1952-8. PubMed ID: 12847388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
